Chen-Jui Ho1, Shih-Hsuan Chen1, Chih-Hsiang Lin1, Yan-Ting Lu1, Che-Wei Hsu1, Meng-Han Tsai1,2. 1. Department of Neurology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, Taiwan. 2. School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Abstract
Purpose: Concerns of drug-drug interactions (DDIs) between anti-seizure medications (ASMs) and non-vitamin K oral anticoagulants (NOACs) have emerged in recent case reports and guidelines. Theoretically, the induction of hepatic cytochrome P450 3A4 (CYP3A4) enzyme and permeability glycoprotein (P-GP) efflux transporter protein systems may reduce the effect of NOACs. We aimed to investigate whether such DDIs are clinically relevant in a real-world situation. Methods: We retrospectively reviewed 320 ischemic stroke patients with atrial fibrillation (Af) and grouped them according to different potential interactions with CYP3A4 and P-GP. Ischemic stroke events, transient ischemic attack (TIA) events, follow-up duration, baseline characteristics, concomitant ASMs, and stroke risk factors were collected. Statistical analysis included Kaplan-Meier survival curves and the log-rank test. Results: Overall, 320 ischemic stroke with Af patients received NOACs. Among the NOAC users, 75 also took ASMs, including 56 that have potential DDIs: 43 (13.4%) were categorized as potential CYP and P-GP DDIs and 13 (4.1%) as P-GP-only DDIs. The remaining 264 (82.5%) patients were used as controls including 19 exposed to nonsignificant DDI ASMs and 245 patients without ASM exposure. The incidence rates of recurrent stroke/TIA events in both CYP3A4 and P-GP DDIs, P-GP DDIs only, and no DDIs were 7.5, 2.1, and 8.4/100 person-years, respectively. Kaplan-Meier survival curves and the log-rank test did not show significant differences among the groups. Conclusions: The recurrent stroke rate of NOAC users with potential DDIs was not higher than in those without potential DDIs in this single-institute study. Our results suggest that theoretical interactions between ASMs and NOACs may not be as severe as previously thought in a real-world situation.
Purpose: Concerns of drug-drug interactions (DDIs) between anti-seizure medications (ASMs) and non-vitamin K oral anticoagulants (NOACs) have emerged in recent case reports and guidelines. Theoretically, the induction of hepatic cytochrome P450 3A4 (CYP3A4) enzyme and permeability glycoprotein (P-GP) efflux transporter protein systems may reduce the effect of NOACs. We aimed to investigate whether such DDIs are clinically relevant in a real-world situation. Methods: We retrospectively reviewed 320 ischemic strokepatients with atrial fibrillation (Af) and grouped them according to different potential interactions with CYP3A4 and P-GP. Ischemic stroke events, transient ischemic attack (TIA) events, follow-up duration, baseline characteristics, concomitant ASMs, and stroke risk factors were collected. Statistical analysis included Kaplan-Meier survival curves and the log-rank test. Results: Overall, 320 ischemic stroke with Afpatients received NOACs. Among the NOAC users, 75 also took ASMs, including 56 that have potential DDIs: 43 (13.4%) were categorized as potential CYP and P-GP DDIs and 13 (4.1%) as P-GP-only DDIs. The remaining 264 (82.5%) patients were used as controls including 19 exposed to nonsignificant DDI ASMs and 245 patients without ASM exposure. The incidence rates of recurrent stroke/TIA events in both CYP3A4 and P-GP DDIs, P-GP DDIs only, and no DDIs were 7.5, 2.1, and 8.4/100 person-years, respectively. Kaplan-Meier survival curves and the log-rank test did not show significant differences among the groups. Conclusions: The recurrent stroke rate of NOAC users with potential DDIs was not higher than in those without potential DDIs in this single-institute study. Our results suggest that theoretical interactions between ASMs and NOACs may not be as severe as previously thought in a real-world situation.
Authors: Jon Marc Finamore; Michael R Sperling; Tingting Zhan; Maromi Nei; Christopher T Skidmore; Scott Mintzer Journal: Epilepsia Date: 2016-07-11 Impact factor: 5.864
Authors: S Eyal; J G Lamb; M Smith-Yockman; B Yagen; E Fibach; Y Altschuler; H S White; M Bialer Journal: Br J Pharmacol Date: 2006-08-07 Impact factor: 8.739
Authors: Yogita Ghodke Puranik; Angela K Birnbaum; Susan E Marino; Ghada Ahmed; James C Cloyd; Rory P Remmel; Ilo E Leppik; Jatinder K Lamba Journal: Pharmacogenomics Date: 2013-01 Impact factor: 2.533
Authors: Michael L Lim; Sherene S Min; Joseph J Eron; Richard J Bertz; Marjorie Robinson; Andrea Gaedigk; Angela D M Kashuba Journal: J Acquir Immune Defic Syndr Date: 2004-08-15 Impact factor: 3.731
Authors: Marian Galovic; Nico Döhler; Barbara Erdélyi-Canavese; Ansgar Felbecker; Philip Siebel; Julian Conrad; Stefan Evers; Michael Winklehner; Tim J von Oertzen; Hans-Peter Haring; Anna Serafini; Giorgia Gregoraci; Mariarosaria Valente; Francesco Janes; Gian Luigi Gigli; Mark R Keezer; John S Duncan; Josemir W Sander; Matthias J Koepp; Barbara Tettenborn Journal: Lancet Neurol Date: 2018-02 Impact factor: 44.182